Aligos Secures Fast Track Designation, Expands HBV Trial Amid Financial Strain
Event summary
- Aligos' pevifoscorvir sodium received FDA Fast Track Designation for chronic HBV, validating unmet medical need.
- Phase 2 B-SUPREME trial interim analysis shows positive outcomes, with sample size increased to 100 participants.
- Aligos secured a $25M upfront deal with Amoytop for Greater China rights, with $420M in potential milestones.
- Q1 2026 financials show $23M net loss, with cash expected to last into Q4 2026.
- ALG-170675 ASO for HBV begins IND-enabling studies, funded by Amoytop.
The big picture
Aligos' progress in HBV treatment comes amid a competitive landscape where regulatory designations and strategic partnerships are critical for differentiation. The $420M milestone potential with Amoytop underscores the value of Greater China market access, but financial losses highlight the balance between growth and burn rate. The company's ability to execute on multiple fronts—clinical trials, regulatory approvals, and partnerships—will determine its long-term viability.
What we're watching
- Regulatory Momentum
- Whether the Fast Track Designation accelerates pevifoscorvir sodium's path to market.
- Financial Sustainability
- How long Aligos can sustain operations with current cash reserves.
- Clinical Trial Success
- The pace at which B-SUPREME trial data could shift investor sentiment.
Related topics